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Abstract Dengue vaccine development is considered a glob-
al public health priority, but the antibody-dependent enhance-
ment (ADE) issues have critically restricted vaccine develop-
ment. Recent findings have demonstrated that pre-membrane
(prM) protein was involved in dengue virus (DENV) infection
enhancement. Although the importance of prM antibodies
have been well characterized, only a few epitopes in DENV
prM protein have ever been identified. In this study, we
screened five potential linear epitopes located at positions
pr1 (1-16aa), pr3 (13-28aa), pr4 (19-34aa), pr9 (49-64aa),
and pr10 (55-70aa) in pr protein using peptide scanning and
comprehensive bioinformatics analysis. Then, we found that
only pr4 (19-34aa) could elicit high-titer antibodies in Balb/c
mice, and this epitope could react with sera from DENV2-
infected patients, suggesting that specific antibodies against
epitope peptide pr4 were elicited in both DENV-infected mice
and human. In addition, our data demonstrated that anti-pr4
sera showed limited neutralizing activity but significant ADE
activity toward standard DENV serotypes and imDENV.
Hence, it seems responsible to hypothesize that anti-pr4 serum
was infection-enhancing antibody and pr4 was infection-
enhancing epitope. In conclusion, we characterized a novel
infection-enhancing epitope on dengue pr protein, a finding
that may provide new insight into the pathogenesis of DENV
infection and contribute to dengue vaccine design.
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Introduction
Dengue virus (DENV1-4) causes the most significant
arboviral disease in the tropical and subtropical areas of the
world, with an estimated 390 million infections per year
(Guzman and Kouri 2002). While most DENV infections are
asymptomatic or lead to self-limited dengue fever (DF), a
growing number of patients present potentially fatal clinical
manifestations including dengue hemorrhagic fever (DHF)
and dengue shock syndrome (DSS) (Bhatt et al. 2013). Al-
though infection with DENVis a growing global public health
concern and imposes one of the largest socioeconomic bur-
dens in the world, approved vaccine remains unavailable
despite decades of effort (Coller and Clements 2011;
Miller 2010).
The immunopathogenesis of DENVinfection is still poorly
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DHF/DSS is associated with sequential infection with differ-
ent serotypes (Gubler 2006). Also, primary infection of infants
born to dengue-immune mothers may be at greater risk of
developing severe disease (Simmons et al. 2007). The hypoth-
esis of antibody-dependent enhancement (ADE) of infection
has been postulated because of these observations. It is rea-
soned that subneutralizing antibodies promoted virus uptake
into Fc receptor-bearing cells, leading to increased DENV-
infected cells and eventually a higher virus load (Halstead
1970; Halstead and O’Rourke 1977; Halstead 2003). Hence,
a successful and safe vaccine must be tetravalent, capable of
providing long-term protection against all four serotypes si-
multaneously (Guy et al. 2011).
Dengue is a single-stranded, positive-sense, RNA virus
with a genome of approximately 11 kb. The virion contains
three structural (capsid (C), pre-membrane (prM), and enve-
lope (E)) and seven nonstructural (NS) proteins (NS1, NS2a,
NS2b, NS3, NS4a, NS4b, and NS5). prM is a 166-amino-acid
protein and acts as a chaperone for correct folding of the E
protein during virus assembly and maturation (Li et al. 2008;
Mukhopadhyay et al. 2005). prM contains a furin cleavage
site and is cleaved by the host cell endoprotease furin into a
C-terminal M protein and an N-terminal 91-amino-acid pre-
cursor peptide (pr protein), resulting in the formation of ma-
ture infectious virus (Yu et al. 2008). Interestingly, cells infect-
ed with DENV secrete a heterogeneous mixture varying from
fully mature (containingM), partially mature virions (contain-
ing a mixture of prM and M) to fully immature (containing
prM) due to inefficient cleavage of prM to M by furin during
DENV maturation (Rodenhuis-Zybert et al. 2008; Cherrier
et al. 2009; Junjhon et al. 2010). It has been proved that fully
immature virus particles are inherently noninfectious whereas
fully mature and partially mature virus are infectious
(Rodenhuis-Zybert et al. 2008, 2010, 2011; Dejnirattisai
et al. 2010). Additionally, the enhancement or neutralization
effect of antibodies seems to be dependent on the maturation
state of virions (Dejnirattisai et al. 2010; Rodenhuis-Zybert
et al. 2010; Nelson et al. 2008).
It has been previously reported that anti-prM antibodies are
commonly found in sera of patients with DENV infection
(Dejnirattisai et al. 2010; Bray and Lai 1991; Cardosa et al.
2002; Se-Thoe et al. 1999). However, the potential role of prM
antibodies during DENV infection was long overlooked as
numerous functional studies have revealed that fully immature
particles are noninfectious (Colpitts et al. 2011). Interestingly,
recent studies on mouse and human antibodies showed that
prM antibodies render virtually noninfectious immature
DENV particles highly infectious (Dejnirattisai et al. 2010;
Rodenhuis-Zybert et al. 2010; Chan et al. 2012). In addition,
anti-prM antibodies are found to play important roles in pa-
tients with both primary infection and second infection
(Dejnirattisai et al. 2010; Lai et al. 2008). Furthermore, many
studies have suggested that these antibodies against prM do
not well neutralize DENV infection but potently promote
ADE infection among four DENV serotypes (Dejnirattisai
et al. 2010; Beltramello et al. 2010). It has also been suggested
that anti-prM antibodies could enhance wild-type DENV in-
fection (Huang et al. 2005, 2006) and increase disease severity
in infants upon primary infection (Chau et al. 2009). Most
importantly, previous study showed a positive correlation be-
tween the circulating prM antibody level and disease severity
(Rai et al. 2008). Taken together, these studies suggest that
prM-specific monoclonal antibodies (mAbs) have a potential
role to enhance DENV infection in humans and thus may
contribute to the development of severe disease.
A recent report detecting the acute B cell response in den-
gue patients has found that DENV infection results in signif-
icant B cell activation at days 4–7 after onset of fever
(Balakrishnan et al. 2011). prM protein, like E protein, is a
major target in the humoral immune response to DENV
(Cardosa et al. 2002; Beltramello et al. 2010). Epitopes are
the focus of pathogenesis research as well as the development
of vaccine and diagnostic reagent (Wu et al. 2001, 2003; Jiang
et al. 2010). Epitopes in the E (Li et al. 2012; de Alwis et al.
2012; Lin et al. 2012; Hughes et al. 2012; Wahala et al. 2012),
NS1( Wu et al. 2001, 2003; Jiang et al. 2010; Steidel et al.
2012), NS4a, and C (Anandarao et al. 2005) have been well
mapped. Although there have been attempts to locate the epi-
topes of prM (Falconar 1999; Huang et al. 2008; Song et al.
2013; Luo et al. 2013), the functional roles of the prM protein
in DENV infection and the precise antigenic structures of prM
are not yet fully understood. Thus, in this study, we mapped
the potential B cell epitopes in the pr protein of DENV with
peptide scanning and comprehensive bioinformatics analysis.
We also investigated the neutralizing versus enhancing capac-
ity of antisera of epitope peptide pr4 toward standard DENV1-
4 particles and imDENV particles.
Materials and methods
Cells and viruses
C6/36 cells, baby hamster kidney-21 (BHK-21) cells, human
adenocarcinoma LoVo cells, and human erythroleukemic
K562 cells were maintained as previously described (Luo
et al. 2013). All cells were purchased from ATCC.
DENV1 strain Hawaii (GenBank EU848545), DENV2
strain New Guinea C (NGC) (GenBank AF038403), DENV3
strain H87 (GenBank M93130), DENV4 strain H241
(GenBank AY947539), and JEV (GenBank AF315119) were
propagated on C6/36 cells, while fully imDEVN2 NGC strain
was produced on furin-deficient LoVo cells as described be-
fore (Rodenhuis-Zybert et al. 2008; Luo et al. 2013). The
infectious titers of virus particles were detected by plaque
assay on BHK-21 cells and viral RNA levels were measured
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by real-time quantitative RT-PCR (qRT-PCR) (Luo et al.
2012). All viruses were kindly provided by Chinese Center
for Disease Control and Prevention, Beijing, China. All virus-
es were deposited in GenBank.
Antibodies and human serum samples
2H2 (IgG2a anti-DENV1-4 prM) and 4G2 (IgG2a anti-all
flavivirus E) hybridomas were purchased from ATCC.
To generate polyclonal antibody (pAb) against prM, the
DENV-2 prM protein was expressed in E. coli and then puri-
fied by electroelution. The purified protein was used to immu-
nize adult male New Zealand rabbits to produce pAb directed
to prM. Anti-prM pAb was purified by caprylic acid–ammo-
nium sulfate precipitation and protein A affinity column
(GenScript, USA); then, the specificity and titer of the anti-
body were verified byWestern blot and enzyme-linked immu-
nosorbent assay (ELISA) (Feng et al. 2013).
Human serum samples were obtained and identified as de-
scribed before (Luo et al. 2013). The use of human sera was
approved by the ethical committee of Haizhu District Center
for Disease Control and Prevention of Guangzhou, China. The
study was also approved by the Ethics Committee of Sun Yat-
sen University.
Peptide synthesis and epitope mapping using anti-prM
pAb
Fourteen overlapping peptides (each with 16 amino acids,
overlap of 10) covering the pr protein were designed and
synthesized (purity >95 %, China Peptides Co., Ltd)
(Table 1). Then, the predominant linear B epitopes on pr pro-
tein were mapped by ELISA using anti-prM pAb and 14 over-
lapping peptides.
ELISA
To screen specific epitopes that directly bind with the pr pro-
tein, ELISA was performed with anti-prM pAb. The ELISA
plate was coated with 100 μl synthetic peptides at a concen-
tration of 10 μg/ml at 4 °C overnight and blocked at 37 °C for
2 h. After washing three times with PBS with 0.1 % Tween-20
(PBST), the plates were incubated with 100 μl anti-prM pAb
diluted in 1:200 at 37 °C for 1 h. Bound antibodies were
detected with 1:5000 diluted HRP-conjugated goat-anti-
rabbit IgG at 37 °C for 45 min. Then, plates were washed
three times and incubated with TMB substrate. The reaction
was stopped with 2 NH2SO4, and the plates were measured at
450 nm using a microplate autoreader.
Bioinformatics analysis of DENV2 pr B cell epitopes
The potential linear epitope on pr protein was predicted using
DNASTAR software and ExPaSy multiple bioinformation
software as described previously (Luo et al. 2013).
Competitive-inhibition assay
The ELISA plate was coated with anti-prM pAb. Next, syn-
thetic peptide was added 0.1 μg per well and purified prM
protein was added simultaneously. Then, the same procedures
as described in BELISA^were followed.
Immunization assay and protection assay in adult Balb/c
mice
All procedures involving animals were approved by the Ani-
mal Experimentation Ethics Committee of Sun Yat-sen Uni-
versity and carried out by a licensed individual with an ethical
approval number of 2012/0081.
Considering the results of peptide scanning and bioinfor-
matics analysis together, we screened five predominant linear
B epitopes located at regions pr1 (1-16aa), pr3 (13-28aa), pr4
(19-34aa), pr9 (49-64aa), and pr10 (55-70aa). Then, we chose
epitope peptides (pr1, pr3, pr4, pr9, and pr10) and control
peptide PM10 (SQNPPHRHQS) to immunize Balb/C mice
and collected anisera for further study as described previously
(Luo et al. 2013). The antibody titer of mice sera was detected
by using ELISA.
The protection experiment was performed as described pre-
viously (Luo et al. 2013). The viral RNA levels of serum
samples were detected using qRT-PCR (Luo et al. 2012). All
animals were euthanized by using carbon dioxide (CO2)
Table 1 A total of 14
overlapping peptides of pr protein
(each with 16 amino acids,
overlap of 10)
Peptide Peptide sequence and location Peptide Peptide sequence and location
pr1 1fhlttrngephmivsr16 pr8 43elcedtityncpllrq58
pr2 7ngephmivsrqekgks22 pr9 49ityncpllrqnepedi64
pr3 13ivsrqekgksllfkte28 pr10 55llrqnepedidcwcns70
pr4 19kgksllfktengvnmc34 pr11 61pedidcwcnststwvt76
pr5 25fktengvnmctlmamd40 pr12 67wcnststwvtygtcta
82
pr6 31vnmctlmamdlgelce46 pr13 73twvtygtctatgehrr88
pr7 37mamdlgelcedtityn52 pr14 79tctatgehrrekr91
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according to NC3Rs standard procedures, and the experiment
was terminated.
Plaque reduction neutralization test (PRNT)
and antibody-dependent infection enhancement (ADE)
assay
To determine the ability of prM-specific antibodies to neutral-
ize or enhance DENVinfection in vitro, PRNTandADE assay
were carried out on BHK-21 cells and K562 cells respectively
as described in our previous study (Luo et al. 2013).
Flow cytometry
The infected K562 cells were fixed, permeabilized, and
stained with 4G2 conjugated to Alexa-Fluor-488 (Invitrogen).
The percent of infected cells was determined by flow
cytometry.
Statistical analysis
Statistical analyses were performed in GraphPad Prism5.0
software. ANOVATukey’s posthoc statistical tests were used
for pairwise comparisons of multiple groups. A p value of less
than 0.05 was considered statistically significant.
Results
Mapping of the antigenic epitopes on the pr protein using
anti-prM pAb
To identify the potential antigenic epitopes on the pr
protein, 11 partially overlapping peptides (pr1–pr14)
were screened by ELISA using anti-prM pAb at various
dilutions. The results showed that seven peptides (pr1,
pr3, pr4, pr6, pr9, pr10, and pr11) were recognized by
anti-prM pAb (Fig. 1), suggesting that these peptides
may be the potential B cell epitopes in pr protein. All
the other seven overlapping peptides and control peptide
PM10 failed to bind with pAb against prM. Our previ-
ous study (Luo et al. 2013) has reported that the poten-
tial linear epitopes on pr protein predicted using DNAS
TAR software and ExPaSy multiple bioinformation soft-
ware were located at regions 3-12aa, 12-26aa, 55-66aa,
and 82-91aa (Fig. 2). Considering the results of peptide
scanning and bioinformatics analysis together, five pre-
dominant epitope peptides (pr1, pr3, pr4, pr9, and pr10)
were chosen to immunize Balb/C mice for further study.
Fig. 2 General evaluation of DENV2-pr epitopes with bioinformation
software. a Hopp and Wood hydrophilicity, b Granthan polarity, c
Bhaskaran and Ponnuswamy flexibility, d Deleage and Roux alpha-
helix regions, e Deleage and Roux beta-turn regions, f Jameson and
Wolf antigenicity, and g Emini accessibility
Fig. 1 Comprehensive
identification of linear B cell
epitopes in DENV2 pr protein
using anti-prM pAb by ELISA.
Seven potential B cell epitopes in
pr protein were mapped. prM pAb
was diluted 200-fold (a), 1000-
fold (b), 5000-fold (c), and
10,000-fold (d). PM10 was used
control peptide. Data are
expressed as means of at least
three independent experiments.
The error bars represent standard
deviations (SD). If there is no
error bar, it is not that no
variations among three
independent experiments but that
the variations are too small to
show in the figure
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Immunogenicity of synthetic peptides on Balb/c mice
According to ELISA results, high titer of antibodies was only
found in mice immunized with pr4. The antibody titer of anti-
pr4 sera was remarkably higher than that of the antisera from
groups of pr1, pr3, pr9, pr10, PM10, and PBS at any time
point (p<0.05). Furthermore, antibody titers of pr4 increased
progressively with each sequential immunization. Thus, im-
munization with pr4 elicits high-titer antibodies in Balb/c
mice (Fig. 3).
Protection response in adult Balb/c mice
As shown in Fig. 4, high levels of viral RNA in all groups
were observed at days 0.25 and 1 post-infection, and the viral
RNA levels in the pr4 group were significantly higher than
that in the other groups (pr1, pr3, pr6, pr9, PM10, and PBS) at
days 0.25 and 1 post-infection (p<0.05). However, all groups
showed a rapidly decreased viremia levels at days 2, 3, 4, and
5 post-infection.
Characterization of epitope peptide pr4
To analyze the conservation of epitope peptide pr4 (19-34aa),
we performed a sequence alignment of the pr protein se-
quences of DENV1-4, YFV, WNV, JEV, and TBEV using
DNASTAR software. Alignment results showed that pr4 epi-
tope sequence was highly conserved among four DENV se-
rotypes but not among other flaviviruses (Table 2).
We next evaluated whether the synthetic peptide pr4 could
be recognized by anti-DENV1-4 mice sera. Synthetic peptide
pr4 could react with anti-DENV1-4 mice sera but not with
anti-JEV mice sera and normal mice sera (NMS) (Fig. 5a),
suggesting that synthetic peptide pr4 is a DENV serocomplex
cross-reactive epitope-based peptide.
To prove further that synthetic peptide pr4 was the epitope
of pr protein, a peptide competitive inhibition assay was per-
formed to determine whether the pr4 peptide competed with
prM protein for reactivity with anti-prM pAb. The reaction
activity of anti-prM pAb with prM protein was inhibited
markedly by pr4 in a concentration-dependent manner
(Fig. 5b).
Then, we confirm the reactivity of synthetic peptide pr4
with 20 DENV2 patient serum samples. As shown in
Fig. 5c, d, pr4 was able to react with sera from 18 patients
infected with DENV2. The sensitivity of pr4 serologic test
was 90 %. In addition, patients showed difference in the level
of antibody. However, all of the sera from 20 healthy adults
failed to bind with pr4. These results demonstrated that spe-
cific antibody response against pr4 epitope was elicited during
natural DENV infection.
Neutralizing activities of anti-pr4 sera
Plaque reduction neutralization test results showed that
anti-pr4 sera failed to completely neutralize infection
with the neutralization level varying from 33 to 60 %,
and the partial neutralization was cross-reactive among
four DENV serotypes (Fig. 6). Anti-pr4 sera, like many
other prM antibodies, did not exhibited high neutraliz-
ing activity. Also, virtually noninfectious imDENV was
neutralized by anti-pr4 sera and the titration curve for
standard DENV2 and imDENV2 were similar (Fig. 6).
These results suggest that anti-pr4 sera exhibited weak
neutralizing activities against standard DENV-4 and
imDENV2.
ADE activities of anti-pr4 sera
The flow cytometry results indicated that anti-pr4 sera
was able to enhance infection varying from 6.3 to
87.6 % over a wide range of antibody concentration
among four DENV serotypes (Fig. 7a). Then, we detect-
ed enhancement of imDENV2 infection using a constant
amount of virus particles identical to standard DENV2.
We found that infection of virtually noninfectious
imDENV was also significantly enhanced by anti-pr4
sera. To further confirm the enhancing capacity of
anti-pr4 sera, we evaluated viral RNA copies in infected
supernatants using qRT-PCR (Fig. 7b). In agreement
with flow cytometry results, anti-pr4 sera caused a sig-
nificant increase of viral load over a large antibody
Fig. 3 Serum antibody titers induced in Balb/Cmice immunizedwith the
synthetic peptides. Seven groups (pr1, pr3, pr4, pr9, pr10, PM10, and
PBS), ten mice for every group, were immunized three times with
100 μg of immunogens. All peptides were coupled to KLH before
immunization. PM10 and PBS were used as controls. The antisera were
collected on week 2, 4 and 6 via tail vein, and the antibody titer of mice
sera was detected by ELISA. The antibody titer of anti-pr4 sera was
remarkably higher than that of the antisera from groups of pr1, pr3, pr9,
pr10, PM10, and PBS at any time point. Data are expressed asmeans of at
least three independent experiments. The error bars represent standard
deviations (SD); *p<0.05 vs other groups (pr1, pr3, pr9, pr10, PM10, and
PBS)
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concentration range (p<0.05). In summary, these results
suggest that anti-pr4 sera showed significant ADE activ-
ities toward standard DENV and imDENV2.
Discussion
Recent findings demonstrated that anti-prM antibodies play
critical roles in human immune responses to DENV. These
antibodies showed limited neutralizing activity but significant
ADE activity (Dejnirattisai et al. 2010; Rodenhuis-Zybert
et al. 2010, 2011; Chan et al. 2012; Lai et al. 2008; Beltramello
et al. 2010; Huang et al. 2006). Although the importance of
prM antibodies has been well reported, the precise antigenic
structures and the functional roles of the prM protein remain
poorly understood. Thus, in this study, we identified the po-
tential B cell epitopes in the dengue pr protein and investigat-
ed the ability of antibody against epitope peptide pr4 to en-
hance infection of standard DENV1-4 and imDENV2.
In the present study, by using peptide scanning and bioin-
formatics analysis, we mapped five potential linear B cell
epitopes (pr1, pr3, pr4, pr9, and pr10) in the dengue pr protein.
However, immunization assay results showed that only epi-
tope peptide pr4 was capable of inducing strong humoral im-
mune response in mice and showed to be highly immunogen-
ic. Sequence alignment results demonstrated that pr4 is a
DENV serocomplex cross-reactive epitope peptide. In our ex-
periments, epitope peptide pr4 showed strong reactivity with
mouse antisera against DENV1-4 but not with anti-JEV mice
sera. Previous studies have reported that anti-prM antibodies
could distinguish infection with DENV from infection with
JEV (Cardosa et al. 2002; Hua et al. 2010). To our knowledge,
cross-reactivity among flaviviruses has been a great diagnostic
obstacle, especially for members of DENV. Hence, epitope
peptide pr4 could be potentially applied in serological moni-
toring and differential diagnosis of DENV infection. Most,
importantly, human sera from patients infected with DENV2
also specifically recognized pr4, suggesting that epitope pep-
tide pr4 may be valuable for the further development of a
DENV-specific diagnostic reagent. Together, these results
showed specific antibodies against epitope peptide pr4 were
elicited in both DENV-infected mice and human, indicating
the importance of pr4 epitope during natural DENV infection.
Fig. 4 Viral RNA copy numbers in immunized mice after infected with
DENV2 NGC strain. Two weeks after the last immunization, mice were
inoculated intraperitoneally with 106 PFU DENV2. Viral RNA copy
numbers of sera were measured at days 0.25, 1, 2, 3, 4, and 5 post-
infection by qRT-PCR. PM10 and PBS were used as controls. The viral
RNA copy numbers in the pr4 group were significantly higher than that in
the other groups (pr1, pr3, pr6, pr9, PM10, and PBS) at days 0.25 and 1
post-infection. Data are expressed as means of at least three independent
experiments. The error bars represent standard deviations (SD); *p<0.05
vs other groups (pr1, pr3, pr9, pr10, PM10, and PBS)
Table 2 Sequence alignment of amino acid residues 19 to 34 of the pr
proteins of flaviviruses









a The protein sequences of DENV1, DENV2, DENV3, DENV4, WNV,
JEV, YFV, and TBEVwere retrieved fromGenBank with accession num-
bers EU848545, AF038403, M93130, AY947539, DQ211652,
AF315119, X03700, and AY182009, respectively
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Our data in this study showed that other four synthetic
peptides (pr1, pr3, pr6, and pr9) could not induce high anti-
body titer in mice. Synthetic peptides representing specific
regions of proteins can induce humoral immune responses
(Vázquez et al. 2002). It has been reported that short peptide
may not exactly imitate the structural of homologous se-
quence in the native protein (Jemmerson and Hutchinson
1990), because other factors such as neighboring residues
and H bonds (within protein) have also influenced the struc-
ture obtained by short stretches in whole protein. Most impor-
tantly, peptides must contain potential antigenic sites to elicit
B cell interaction.
It has been well demonstrated that the anti-prM antibody
mediated DENV infection enhancement and play critical roles
in DENV pathogenesis (Rodenhuis-Zybert et al. 2008, 2010;
Dejnirattisai et al. 2010; Lai et al. 2008; Beltramello et al.
2010; Huang et al. 2006, 2008; Luo et al. 2013). In agreement
with these studies, antibody against epitope peptide pr4 de-
scribed in this study exhibited broad cross-reactivity and poor
neutralizing activity but potent ADE activity toward the four
standard DENV serotypes and imDENV. In addition, we
found that the epitope peptide pr4 indeed induce enhancing
antibodies and lead to an increase of viral load in mice sera
during protection assay in vivo. Thus, we concluded that anti-
pr4 serum was infection-enhancing antibody and pr4 was
infection-enhancing epitope. Taken together, we further con-
firmed prM antibodies could enhance infectivity of DENVand
demonstrated the importance of prM antibodies during DENV
Fig. 5 Characterization of epitope peptide pr4. a ELISA reactivities of
synthetic peptide pr4 with immunized mice sera. Synthetic peptide pr4
could react with anti-DENV1-4 mice sera but not with anti-JEVmice sera
and normal mice sera (NMS). b Competitive inhibition of prM protein
binding to anti-prM pAb by synthetic peptide pr4. Competitive ELISA
was performed using pr4 as competitor of prM protein. The reaction
activity of anti-prM pAb with prM protein was inhibited markedly by
pr4 in a concentration-dependent manner. c, d ELISA reactivities of
synthetic peptide pr4 with sera from 20 DENV2-infected patients (c)
and 20 healthy adults (d). pr4 was able to react with sera from 18
patients infected with DENV2 but not with sera from healthy adults.
PM10 was used as control. Data are expressed as means of at least
three independent experiments. The error bars represent standard
deviations (SD). If there is no error bar, it is not that no variations
among three independent experiments but that the variations are too
small to show in the figure
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infection. To date, the molecular mechanism of neutralization
and ADE is still not well described. It has been demonstrated
that antibodies against prM can enhance infectivity of prM-
containing DENV particles by facilitating efficient binding
and cell entry of virus-antibody complexes into Fc
receptor-bearing cells (Dejnirattisai et al. 2010;
Rodenhuis-Zybert et al. 2010).
Anti-pr4 sera showed different neutralizing and ADE ac-
tivities against different DENV serotypes, suggesting the
structural differences in this region that perhaps involve the
polarities and side chain orientations of structurally
neighboring amino acids. In addition, the well-exposed epi-
topes available for antibody recognition in the structural
change process are likely to vary in different viruses (Nelson
et al. 2008; Roehrig 2003). Also, it has been demonstrated that
differences in DENV serotype or even strain might be a factor
in generation of varying degrees of ADE and dengue severity
(Endy et al. 2004; Vaughn et al. 2000; Goncalvez et al. 2007).
The differences in ADE between serotypes have become the
main obstacle to study immunopathogenesis of DENV
infection and develop dengue vaccines. Dejnirattisai et al.
(2010) and Beltramello et al. (2010) also have found that four
DENV serotypes showed different degrees of ADE.
Although dengue vaccine development is considered a
global public health priority, approved vaccines remain un-
available due to the cross-reactive among four DENV sero-
types and ADE phenomenon. As reported in the present study
and recent reports, prM-specific antibodies are capable of re-
storing and enhancing the infectivity of prM-containing im-
mature and partially mature (Rodenhuis-Zybert et al. 2008,
2010; Dejnirattisai et al. 2010; Lai et al. 2008; Beltramello
et al. 2010; Huang et al. 2006, 2008; Luo et al. 2013). Hence,
a better vaccine design approach that minimizes the ADE
responses elicited by enhancing epitopes in prM protein may
contribute to the success of dengue vaccines. Consequently, it
may be important to map various kinds of prM epitopes,
which are responsible for enhancing antibodies or neutralizing
antibodies. However, only a few epitopes in DENV prM pro-
tein have been well characterized (Falconar 1999; Huang et al.
2008; Song et al. 2013; Luo et al. 2013). In this study, we map
a novel infection-enhancing epitope on dengue pr protein, a
finding that may provide new insight into the pathogenesis of
DENV infection and contribute to dengue vaccine design.
Fig. 6 Neutralizing activities of anti-pr4 sera toward standard DENV1-4
and imDENV2. Fifty PFU viruses were mixed with 2-fold serially diluted
antibody for 1 h at 37 °C. Neutralizing activities were detected by plaque
reduction assay using BHK-21 cells. Anti-pr4 sera show poor
neutralizing activities with standard DENV1-4 and imDENV2. Data are
expressed as means of at least three independent experiments. The error
bars represent standard deviations (SD). If there is no error bar, it is not
that no variations among three independent experiments but that the
variations are too small to show in the figure
Fig. 7 ADE of DENV infection in K562 cells mediated by anti-pr4 sera.
Twofold serially diluted antibodies and an equal volume of DENV (MOI
of 1) were mixed for 1 h at 37 °C and added to K562 cells. a The percent
of infected K562 cells was measured at 3 days post-infection by flow
cytometry. b Viral RNA levels of supernatants were accessed at 4 days
post-infection by qRT-PCR. Anti-pr4 sera showed significant ADE
activities toward standard DENV and imDENV2. NMS was used as
control. Data are expressed as means of at least three independent
experiments. The error bars represent standard deviations (SD). If there
is no error bar, it is not that no variations among three independent
experiments but that the variations are too small to show in the figure.
*p<0.05 vs No Ab
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In conclusion, we screened a DENV serocomplex cross-
reactive epitope pr4 (19-34aa) on pr protein using peptide
scanning and comprehensive bioinformatics analysis, and
found that this epitope was infection-enhancing. These find-
ings may help to understand pathogenesis of DENV infection
and advance the development of dengue vaccine.
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